Hunan, China
Business Type:
Manufacturer/Factory, Trading Company
Registered Capital:
7000000 USD
Plant Area:
>2000 square meters
Management System Certification:
ISO 9001
Average Lead Time:
Peak season lead time: within 15 workdays
Off season lead time: within 15 workdays
OEM/ODM Service
Sample Available
Overseas Agent / Branch

Macleaya Cordata Extract, Bloodroot Extract, Phytochemical Sanguinarine manufacturer / supplier in China, offering Manufacture Macleaya Cordata Extract Sanguinarine 1.5%-50%, Supply High Quality Roselle Extract 10%-30% Polyphenol, Pure Natural Vitamin C Acerola Cherry Extract and so on.

Gold Member Since 2007
Audited Supplier
Supplier Homepage Products Plant Extract Manufacture Macleaya Cordata Extract Sanguinarine 1.5%-50%

Manufacture Macleaya Cordata Extract Sanguinarine 1.5%-50%

Min. Order / Reference FOB Price
1 kg US $1/ kg
Port: Changsha, China
Production Capacity: 5000kgs/Month
Payment Terms: T/T, Paypal
Certification: ISO, FDA, Kosher
Assay Method: HPLC
Application Form: Injection, Lotion, Suppository, Paste, Tablet, Capsule
Application: Medicine, Animal Feed Additive
State: Powder
Extract Source: Macleaya Cordata

You Might Also Like


Basic Info.

Model NO.
Product Name
Macleaya Cordata Extract
Botanical Source
Macleaya Cordata (Willd.) R. Br.
Active Ingredient
Fine Orange Red Powder
Soluble in Water
Molecular Fomular
Molecular Weight
Transport Package
Packed in Fiber Drum, LDPE Bag Inside.
HS Code
 Macleaya Cordata Extract
Active ingredients: Sanguinarine
Molecular Fomular: C20H14NO4
Molecular Weight: 332.09 
Introduction of Sanguinarine
Sanguinarine is a toxic quaternary ammonium salt from the group of benzylisoquinoline alkaloids. It is extracted from some plants, including bloodroot (Sanguinaria canadensis), Mexican prickly poppy Argemone mexicana, Chelidonium majus and Macleaya cordata. It is also found in the root, stem and leaves of the opium poppy but not in the capsule.
Sanguinarine is a toxin that kills animal cells through its action on the Na+-K+-ATPase transmembrane protein. Epidemic dropsy is a disease that results from ingesting sanguinarine.
If applied to the skin, sanguinarine kills cells and may destroy tissue. In turn, the bleeding wound may produce a massive scab, called an eschar. For this reason, sanguinarine is termed anescharotic.
Preliminary pre-clinical in vitro and in vivo studies have demonstrated that sanguinarine causes apoptosis in human cancer cells, and recommend study of sanguinarine as a potential cancer treatment.A study conducted by the Case Western Reserve University in 2000 found that low doses of sanguinarine caused this apoptosis in cancerous human epidermoid carcinoma cells while little reaction from normal human skin cells was observed. However, no products containing sanguinarine are currently approved by the FDA for the treatment of cancer; the FDA warns that unapproved bloodroot preparations are ineffective and dangerous.
Sanguinarine Suppresses Prostate Tumor Growth and Inhibits Survivin Expression
Prostate cancer is a frequently occurring disease and is the second leading cause of cancer-related deaths of men in the United States. Current treatments have proved inadequate in curing or controlling prostate cancer, and a search for agents for the management of this disease is urgently needed. Survivin plays an important role in both progression of castration-resistant prostate cancer and resistance to chemotherapy. Altered expression of survivin in prostate cancer cells is associated with cancer progression, drug/radiation resistance, poor prognosis, and short patient survival. In the present study, the authors performed a cell-based rapid screen of the Prestwick Chemical Library consisting of 1120 Food and Drug Administration-approved compounds with known safety and bioavailability in humans to identify potential inhibitors of survivin and anticancer agents for prostate cancer. Sanguinarine, a benzophenanthridine alkaloid derived primarily from the bloodroot plant, was identified as a novel inhibitor of survivin that selectively kills prostate cancer cells over "normal" prostate epithelial cells. The authors found that sanguinarine inhibits survivin protein expression through protein degradation via the ubiquitin-proteasome system. Sanguinarine induces apoptosis and inhibits growth of human prostate cancer cells and in vivotumor formation. Administration of sanguinarine, beginning 3 days after ectopic implantation of DU145 human prostate cancer cells, reduces both tumor weight and volume. In addition, sanguinarine sensitized paclitaxel-mediated growth inhibition and apoptosis, offering a potential therapeutic strategy for overcoming taxol resistance. These results suggest that sanguinarine may be developed as an agent either alone or in combination with taxol for treatment of prostate cancer overexpressing survivin.


Send your message to this supplier

avatar Ms. Winnie Lee

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now